18/08/2026
In investing, no one bats a thousand, and unfortunately that has certainly been the case for us at Urquhart Partners.
Our recent quarterly update therefore also looked at some of the Fund’s detractors, including an undisclosed healthcare company.
The investment case is similar in many respects to Super Group: disposals of non-core operations have simplified the business, returned significant capital to shareholders and reduced debt.
But there is an important difference. While Super Group’s remaining operations have since improved, that has not been the case here, at least not yet.
The result? The company declined 8% during the quarter after subdued results, while the peer we held as a hedge gained 9% on stronger earnings.
Both sides of the position therefore moved against us.
This highlights an important limitation of hedging. A peer position can reduce exposure to broader sector movements, but it cannot eliminate company-specific operational risk.
The turnaround has taken longer than expected, but we believe the divergence is unlikely to persist indefinitely. The business trades at trough valuation levels, while potentially significant earn-outs and milestone payments from a previous disposal provide an additional source of value not reflected in the current share price.
Since quarter end, a further development involving the purchaser of the disposed assets has potentially added another dimension to this optionality.
The investment hasn’t worked so far.
And the disposals may be complete.
The economic story may not be.